SUPPLEMENTARY MATERIAL AND METHODS

A retrospective case-series study was conducted including prostate cancer patients (PCP) undergoing treatment with apalutamide who were referred to the pharmacovigilance committee due to suspicion of non-tolerable grade 2 or higher ACRs and evaluated by a dermatologist between 04/2021 and 06/2023 in a single tertiary referral centre in Spain.

Skin adverse events were graded according to the CTCAE v5.0. LPT and patch testing were performed in all patients to test all suspicious concomitant drugs according to our clinical practice. LPT was performed either before initiation of oral corticosteroid treatment or at least one month after its cessation. Patch testing was performed at least 3 months after the resolution of the ACR and cessation of treatment. Apalutamide patch tests were prepared with the commercial tablets, diluted at 10% and 30% in petrolatum or water.